Volume 87 Issue 18 | p. 43
Issue Date: May 4, 2009

Ethical Review

GAO finds that ethics review boards for clinical trials are vulnerable to fraud, abuse
Department: Government & Policy

ALTHOUGH SAFEGUARDS are in place to ensure that research involving human subjects is carried out ethically, a recent investigation by the Government Accountability Office (GAO) ironically found that the system for reviewing the ethics of clinical trials is vulnerable to unethical manipulation.

Under federal law, all clinical research including human testing must first be approved by an institutional review board (IRB)—a panel of at least five experts, including one scientist and one nonscientist, . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society